Biovica’s VISION- ‘best possible treatment decisions’ from day one
We envisage a future where every patient receives the best possible therapy on every day of treatment. Where medical decisions are tailored to individual needs rather than practices that work for some but not for others. Our assays will help clinicians predict and monitor response to treatment with unrivaled speed and precision. We will make best-possible-treatment evaluation a reality.
Biovica: Committed to developing and commercializing novel blood-based biomarker assays.
Biovica is a Swedish biotech founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. Our initial focus is breast cancer, a disease responsible for over 600,000 deaths a year. We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development, with the aim of improving outcomes and lowering costs.
Clinical validation of DiviTum®, our lead test, has been selected for support and funding by the European Commission Horizon 2020 phase 2 program.
Biovica’s mission – more informed treatment decisions
Biovica’s biomarker assays can guide clinicians to make more informed decisions about medical treatment and follow-up, thereby delivering the right treatment to the right patient at the right time